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Hepáticas y Digestivas, La Fe Hospital, Valencia, SpainHepatitis C virus (HCV) re-infection of the graft is universal dosing of pegylated interferon alpha (PEG) and/or ribavirin (RBV)
and interferon based antiviral therapy remains at present the
treatment of choice in HCV liver transplant recipients. Apart from
the antiviral effects, interferon and ribavirin have both potent
immunomodulatory properties resulting in a broad range of
immune-related disorders including acute cellular rejection and
chronic ductopenic rejection as well as de novo autoimmune hep-
atitis. Further complicating the picture, HCV infection per se is
associated with a variety of autoimmune phenomena. We discuss
here the immune-mediated complications and their relationship
to chronic HCV and interferon based antiviral therapy.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Hepatitis C virus (HCV) related end-stage liver disease is the lead-
ing indication for liver transplantation worldwide. HCV re-infec-
tion of the graft is universal and associated with accelerated
progression of ﬁbrosis, leading to graft cirrhosis in 10–30% of
patients within 5 years [1,2]. The long-term survival of HCV-posi-
tive liver transplant recipients is, therefore, impaired [3,4].
HCV elimination through interferon alpha (IFN) based antivi-
ral therapy has been shown to improve survival [5–7]. However,
the efﬁcacy of antiviral therapy in liver transplant recipients
remains suboptimal, most studies reporting sustained virological
response (SVR) rates that are at least 10–20% lower than those of
a non-transplant population [6,8,9]. Contributing factors likely
include the obvious need for concomitant immunosuppressive
therapy, the high prevalence of HCV genotype 1 infection
responding poorly to current antiviral regimens [7,10–12] and,
last but not the least, the limited tolerability preventing optimalJournal of Hepatology 20
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Apart from the antiviral effects mediated through the Jak-Stat
signaling pathway, IFN is a potent immunomodulator affecting
both the innate and the adaptive immune system [14–16]. While
the exact mechanism(s) responsible for the anti-HCV effect of RBV
remain(s) to be elucidated, RBV has been shown to exert antiviral,
as well as immunomodulatory effects [15,17]. Given the immuno-
modulatory properties of both agents, it is not surprising that a
broad range of immune-related phenomena and disorders have
been reported in association with IFN-based therapy of HCV
patients [18,19]. In the non-transplant setting, this includes an
autoimmune-type thyroiditis, and rarely, entities, such as sys-
temic lupus erythematosus, type 1 diabetes, and even autoim-
mune-type hepatitis (AIH) [20–22]. Acute cellular rejection
(ACR) and chronic ductopenic rejection are unique to the post-
transplant setting. Both, as well as an ill-deﬁned autoimmune-
type graft hepatitis, have been reported in association with
IFN-based therapy of recurrent HCV after liver transplantation
[7,9,13,23]. Moreover, HCV infection per se is known to be associ-
ated with a variety of autoimmune phenomena and diseases, thus
further complicating the issues of rejection and autoimmune phe-
nomena associated with IFN-based therapy of recurrent HCV [24].
In the following we will focus on acute and chronic rejection,
as well as autoimmune-type graft hepatitis and discuss their
characteristics and potential relationship to recurrent HCV infec-
tion per se and/or IFN-based antiviral therapy.Acute cellular rejection
The overall incidence of ACR in HCV transplanted recipients varies
between 30% and 50% in various studies [25]. The majority of
these studies have examined an early ACR (<6 weeks) post LT.
ACR is a relatively rare, but serious side effect of IFN-based antivi-
ral therapy of HCV recurrence after liver transplantation. The
association between ACR and antiviral therapy was initially
described in renal transplant recipients and was subsequently
reported in liver transplant patients [26,27]. The initial lack of
experience in management of ACR and the fear that it might lead
to a subsequent risk of developing chronic rejection (CR) and ulti-
mately graft loss have hindered for years the acceptance and
generalization of antiviral therapy for recurrence of chronic HCV11 vol. 55 j 207–217
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post liver transplantation. Today, with better knowledge of the
management of ACR and its outcomes, this side effect of IFN-based
antiviral therapy appears less worrisome than in the past.
The reported incidence of ACR during IFN-based therapy
ranges from 0 to 35% (Table 1) [28]. This wide range is partly
explained by heterogeneity among the studies regarding (1) per-
formance of protocol liver biopsies during therapy looking for
evidence of subclinical rejection even in the absence of abnormal
liver tests, (2) the use of PEG rather than regular IFN with or with-
out RBV, and (3) differences in the baseline immunosuppression
regimens [29]. In a retrospective analysis of 23 HCV recipients
who underwent antiviral therapy for HCV recurrence post liver
transplantation, Stravitz et al. reported an incidence of 35% of
ACR diagnosed in a post treatment liver biopsy [30]. The authors
argue that several features of their protocol might have contrib-
uted to this high rate of ACR; these included the practice of pro-
tocol biopsies pre- and post-antiviral therapy allowing the
detection of subclinical ACR, the use of the PEG as opposed to reg-
ular IFN, and, ﬁnally, the late administration of IFN therapy post-
transplant (when maintenance immunosuppression is usually
less intense) [30]. Protocol biopsies (pre- and post-IFN therapy)Table 1. Summary of the acute cellular rejection and chronic rejection in the larger
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208 Journal of Hepatology 201and PEG regimens are currently the standard of practices in many
centers that do not observe a similarly high incidence of ACR. An
important point of the Stravitz study is the fact that only 4 of the
23 patients received a full course of RBV therapy [30]. This might,
at least in part, explain the high incidence of ACR, as it is known
that RBV suppresses proliferation of immune cells in vitro, and,
thus, might protect against ACR [31]. This seems corroborated
by the study of Dumortier et al. who observed an ACR incidence
of 25% among 20 patients treated for HCV recurrence [32]. Here
again only 3 of the 20 patients received a full dose RBV. Indeed,
the reported rate of ACR in most recent studies using the combi-
nation of both drugs is below 10% [7,33–35]. Most importantly, in
all recent randomized studies, the incidence of ACR in HCV-posi-
tive liver transplanted recipients treated with combination anti-
viral therapy for HCV recurrence does not seem to be higher
than that observed in non-treated HCV-positive liver transplant
recipients [36–38].
ACR is often associated with concomitant low or negative
serum HCV RNA. It has been suggested that HCV clearance during
IFN-based therapy improves hepatic microsomal function, which
in turn leads to lower immunosuppressant levels in blood puttingantiviral studies for HCV recurrence post liver transplantation.
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patients at higher risk of development of ACR [39,40]. In an anal-
ysis of 36 HCV patients treated for recurrence of HCV post liver
transplantation, Kugelmas et al. showed that the mean cyclospor-
ine and tacrolimus trough levels measured immediately after
becoming HCV RNA negative were signiﬁcantly lower than those
at baseline (pre-therapy) [39]. Furthermore, they demonstrated
that the overall decrease of calcineurin inhibitor levels after
HCV clearance averaged 32% in responders to antiviral therapy
compared to only 0.98% in non-responders. These data, albeit
preliminary, have alerted transplant physicians to monitor calci-
neurin inhibitor levels closely during the course of antiviral ther-
apy, in particular in patients who respond favorably and clear the
virus. Our practice is to routinely increase baseline immunosup-
pression in all HCV recipients at the initiation of antiviral therapy
in order to lower the probability of triggering ACR at the time of
viral clearance.
The typical manifestation of ACR during antiviral therapy is a
secondary increase of liver function test, in particular the trans-
aminases, after an initial improvement or normalization with
treatment. This is, however, non-speciﬁc and the diagnosisFig. 1. Acute cellular rejection occurring in a patient transplanted for HCV cirrhosi
magniﬁcation 100). (B) Portal tract lymphoid inﬂammation with few eosinophils (arr
eosin, magniﬁcation 400). (C) Portal tract showing portal vein phlebitis. There is su
(hematoxylin and eosin, magniﬁcation 200).
Journal of Hepatology 201requires a liver biopsy (Fig. 1). In 1997, The Banff Working Group
[41], developed a consensus for a common nomenclature along
with a set of histopathological criteria for the diagnosis and grad-
ing of ACR. These include: (a) a mixed, but predominantly mono-
nuclear portal inﬂammation, containing blastic (activated)
lymphocytes, neutrophils, and frequently eosinophils; (b) bile
duct inﬂammation/damage; and (c) phlebitis of portal veins or
terminal hepatic venules. Portal inﬂammation, bile duct damage,
and venous endothelial inﬂammation/damage are each scored
semi-quantitatively on a scale of 0 to 3 (0 = absent, 3 = severe)
[41]. The individual scores are then added to generate an overall
rejection score (rejection activity index, RAI) that can reach a
maximum of 9 in case of severe rejection. Applying this scoring
system presupposes that the diagnosis of rejection is ﬁrst made
based on the aforementioned histological pattern, thus becoming
eligible for severity scoring.
To facilitate the acceptability and in the interest of simplicity,
the Banff group agreed to further provide a global assessment of
the ACR grading based on the overall biopsy appearances. Rejec-
tion is indeterminate if the portal inﬂammatory inﬁltrate fails tos. (A) Liver parenchyma showing sparse lymphocytosis (hematoxylin and eosin,
owhead) and bile duct epithelium inﬁltration by lymphocytes (hematoxylin and
bendothelial inﬁltration by lymphocytes and lifting of endothelial cells (arrow)
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meet the criteria for the diagnosis of ACR, as above. Rejection is
mild if the inﬁltrate fulﬁls the criteria, and is present in a minority
of the triads, conﬁned within the portal tracts. In moderate
rejection, the inﬁltrate expands most or all of the portal tracts.
In severe rejection, in addition to expanding inﬁltrate to most or
all of the portal tracts, there is spill over into periportal areas
and perivenular inﬂammation that extends into the hepatic
parenchyma and is associated with perivenular hepatocyte
necrosis [41].
Because of the potential for progressive injury and graft loss, it
is recommended that any biochemical abnormalities secondarily
appearing during antiviral therapy should prompt an immediate
liver biopsy to rule out histological evidences of ACR. For mild
ACR, the current management is to increase baseline immuno-
suppression level. For moderate to severe forms of ACR (RAI
>4), i.v. boluses of steroids are recommended. A follow up liver
biopsy should be considered in patients with elevated liver
enzymes persisting after treatment of ACR.
Whether antiviral therapy should be discontinued when ACR
is diagnosed is a matter of debate. Many transplant hepatologists
will stop antiviral therapy, at least in case of a moderate or severe
ACR requiring i.v. bolus steroids. Some programs have started to
continue antiviral therapy even in severe ACR cases. Based on our
personal experience, the prognosis of ACR in HCV recipients dur-
ing the course of antiviral therapy is not worse than the ACR in
HCV recipients without antiviral therapy. Clearly more data are
required to resolve this important issue.Chronic rejection
The reported incidence of chronic rejection (CR) in HCV-positive
liver transplant recipients in the absence of IFN treatment varies
between 4% and 8% [42]. Five small studies using PEG IFN therapy
have reported a total of seven cases of CR [30,37,43–45]. Three of
these seven patients had severe ACR which casts some doubt on
the role of IFN-based therapy in directly triggering CR. Recently,
Stanca et al. reported a 17% rate of CR among 70 HCV liver trans-
plant recipients treated with a PEG based regimen in their center
[46]. In contrast to the previous reports, only four of these
patients had previously developed ACR while receiving antiviral
therapy. The authors argue that pegylated formulation of IFN
together with a longer length of therapy may explain this unusual
high rate of CR. Indeed in their series, CR was diagnosed after a
median of 12 months of therapy with PEG and RBV. Six of the
12 patients with CR were treated for more than 12 months with
antiviral therapy when CR was diagnosed. The presence and
severity of previous ACR did not appear to play a role in the
development of CR in this study.
In another series of 67 HCV patients treated for HCV recur-
rence post liver transplantation with either the standard IFN
(n = 31) or PEG (n = 36), Berenguer et al. reported a total of 4
patients with CR. The rate of rejection was 3% in those treated
with standard INF compared to 14% in the PEG group [42]. Three
of the 4 patients achieved SVR of whom two were listed for
re-transplantation.
In our series of 172 LT recipients who underwent IFN based
regimen for HCV recurrence, we observed histological evidence
of CR on the liver biopsies performed during or after antiviral
therapy in only seven (4%) patients, of whom three had achieved
SVR [7]. Three of the seven patients were treated with standard210 Journal of Hepatology 201IFN and the four remaining with PEG. None of these patients
had experienced ACR during the course of antiviral therapy.
Similar to the observation in ACR, it appears that the clearance
of the virus might be associated with CR. In the series by
Berenguer et al., all cases of CR occurred after the patients had
achieved SVR [42]. Similarly, in our series, CR was diagnosed after
12 (4–17) months of therapy when 70% of the patients had unde-
tectable HCV RNA [7]. Similar to the report from Stanca et al. [46],
a majority of patients developing CR in our series had been trea-
ted with INF based regimens for more than one year, thus raising
the question of whether the length of antiviral therapy may have
an impact as a risk factor on the development of CR. No signiﬁ-
cant decrease in calcineurin inhibitor levels was observed in
association with CR [7]. Further studies with larger population
are required to clarify the role of PEG regimen and the length
of antiviral therapy in the development of CR.
CR is deﬁned by histological evidence of atrophy and loss of
both small bile ducts (Fig. 2) and small branches of the hepatic
artery essentially in the portal tracts and perivenular regions
[47]. The bile duct damage in CR appears to be caused by both,
(a) direct immunologic attack and (b) indirectly via ischemic bile
duct injury mediated by changes of the microvasculature (oblit-
erative arteriopathy, small artery/arteriolar loss, and destruction
of the peribiliary capillary plexus) [48].
CR is suspected when a cholestatic liver enzyme pattern
develops during antiviral therapy and imaging has excluded large
bile duct and/or hepatic artery changes as potential etiology of
abnormal liver tests. The diagnosis requires a liver biopsy demon-
strating small duct loss in the portal tracts (vanishing bile duct
syndrome). The aforementioned vascular changes are usually
not sampled in a percutaneous liver biopsy.
CR is histologically divided into early and late stages accord-
ing to the Banff staging system [47]. The clinical implication of
staging is that patients with early stage CR have lesions that
are potentially reversible with increased immunosuppression
and, therefore, may not require re-transplantation. However, in
patients with late CR and no ongoing necroinﬂammatory activity,
additional immunosuppressive therapy is unlikely to be beneﬁ-
cial and re-transplantation may be required.
Overall CR seems to be a relatively rare, but serious complica-
tion of interferon based therapy for HCV recurrence after liver
transplantation. Thus, out of the seven patients developing CR
in our series, three had achieved an SVR, two of the latter died
from graft failure secondary to CR while awaiting liver re-trans-
plantation. Moreover, the pathologic mechanisms involved and
their link to IFN-based therapy remain ill understood.De novo ‘‘autoimmune hepatitis’’ (AIH)
Autoimmune hepatitis (AIH) is a chronic inﬂammatory liver dis-
ease of unknown cause. Multiple factors are felt to play a role in
its pathogenesis. Thus, it is thought that, on a predisposing
genetic background (HLA DR3 and DR4), environmental, pharma-
cological or infectious agents may trigger the condition. The diag-
nosis is based on a scoring system proposed by a group of experts
and recently simpliﬁed to criteria [49]. Among patients trans-
planted for autoimmune related end-stage liver disease, recur-
rent disease occurs infrequently in the early post-transplant
period but may become an issue with prolonged follow-up, with
an incidence in adults ranging from 8% at 1 year to 60% after1 vol. 55 j 207–217
Fig. 2. Chronic rejection. Portal tract with a markedly atrophic bile duct (arrow).
The duct epithelial cells show senescent changes. Their epithelium is attenuated,
more eosinophilic and their nuclei are unevenly spaced. There is no ductular
reaction at the periphery of the portal tract (hematoxylin and eosin, magniﬁca-
tion 400).
Fig. 3. De novo AIH hepatitis/plasma-cell rich hepatitis post HCV treatment with HCV
magniﬁcation 100). (B) Portal tract with lymphoplasmacytic inﬁltrate and mild interfac
showing advanced ﬁbrosis with rounded parenchyma contours surrounded by curved s
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Journal of Hepatology 2015 years of follow-up. The risk is higher in children. While no spe-
ciﬁc immunosuppression has been linked to a higher risk of
recurrence, most studies have emphasized the hazards of discon-
tinuing immunosuppression, particularly steroids. Its reintroduc-
tion is frequently accompanied by an improvement in liver
function tests, generally but not always associated with histo-
logic resolution.
Idiopathic hepatitis with histological characteristics of AIH,
namely the presence of a plasma-cell rich centrilobular inﬁltrate
on liver biopsy [50,51] (Fig. 3), have been described in patients
undergoing liver transplantation for indications other than AIH
[51–55] particularly in the pediatric transplanted population. In
this setting, rejection and steroid dependence are risk factors
associated with this complication. This has been termed de novo
AIH, AIH-like recurrence, graft dysfunction mimicking AIH, or
plasma cell hepatitis. It remains controversial though whether
these cases represent a true AI (alloimmune) process, as opposed
to an atypical manifestation of recurrent disease or of acute or
chronic allograft rejection [50,52,56,57]. Due to the heterogeneity
of patient populations studied, the histological features
described, and the small number of patients included in different
series, these and many questions remain currently unresolved.RNA clearance. (A) Perivenular inﬂammation in zone 3 (hematoxylin and eosin,
e activity (arrow) (hematoxylin and eosin, magniﬁcation 400). (C) Repeat biopsy
epta (green) (Masson trichrome, magniﬁcation 25). HV, hepatic vein.
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Interestingly, an increasing number of such cases with AIH
like features have been reported in recent years in transplant
recipients infected with HCV [56,58]. This includes several cases
in which AIH like features developed in the setting of antiviral
therapy for recurrent HCV infection [58]. The implications are
important because of the potential risks associated with
increased immunosuppression in HCV-infected recipients
[59,60]. Indeed, while the addition of corticosteroids may reduce
the severity of liver inﬂammation in these patients, it occurs at
the expense of enhanced viral replication, potentially resulting
in progressive HCV-related ﬁbrosis and impaired viral clearance
with antiviral therapy [60,61].
The diagnosis is challenging and requires the exclusion of
alternative aetiologies of allograft dysfunction, including
recurrent disease, rejection, biliary complications, and acquired
viral infections, together with a clinical presentation resem-
bling classic AIH, with a particular emphasis on histological
features of AIH, such as centrilobular necrosis with or without
bridging necrosis and a prominent plasma-cell rich inﬁltrate
(Fig. 3). This pattern of immune mediated hepatitis is different
from that usually seen in recurrent HCV (Fig. 4). Rapid
response to corticosteroids remains an important diagnostic
tool [55].
Fiel et al. reported one of the largest studies to date describing
38 HCV-positive liver transplanted recipients with histological
changes compatible with autoimmunity in a post-transplant liver
biopsy performed a mean of 17 (3.6–173.4) months after trans-
plantation [62]. About half of the patients had a history of ACR.
In this series, the histological changes compatible with autoim-
munity were more frequently observed in association with a
recent lowering of maintenance immunosuppression (47% of
cases), or subtherapeutic calcineurin inhibitor levels (35%). ThisFig. 4. Recurrent hepatitis C with involving zone 3 in the same patient depicted in Fig
the hepatic vein (hematoxylin and eosin, magniﬁcation 100). (B) Portal area of same b
(arrow) (hematoxylin and eosin, magniﬁcation 100).
212 Journal of Hepatology 201might suggest the presence of a variant form of ACR, rather than
a true de novo AIH [62]. Rapid resolution of the histological
changes (as early as one month) following therapy (see below),
and low titers of auto-antibodies (<1/160) in the majority of
the patients are additional arguments against the diagnosis of
true de novo AIH [62].
A small number of patients in Fiel’s series were treated. In
those who received speciﬁc therapy, treatment was variable, con-
sisting in either the addition of azathioprine, mycophenolate
mofetil, prednisone, and/or an increase of the calcineurin inhibi-
tor. The fact that steroid therapy was associated with worse
results than with the optimized calcineurin inhibitor dose seems
to imply that steroid therapy may have improved autoimmune
features, but may ultimately have led to a more severe recurrence
of HCV.
Fiel et al. [62] argued that the development of a plasma-cell
rich inﬁltrate in HCV patients post liver transplantation is a var-
iant of rejection rather than AIH based on the following: (i) the
early occurrence of the histological features post liver transplan-
tation,;(ii) previous episodes of ACR; (iii) a rapid resolution of
plasma cell inﬁltrate with increased immunosuppressive treat-
ment in some patients, (iv) absence or low titers of auto-antibod-
ies; and (v) suboptimal immunosuppressive levels or recent
lowering of the immuosuppression in many patients. Interest-
ingly, the fact that an increasing number of such cases were
reported in recent years may be due to the recent trend of more
aggressively weaning immunosuppression in patients trans-
planted for HCV.
In another study by Khettry et al., 10% of HCV patients devel-
oped histological ‘‘AIH like’’ features with moderate to severe
portal, periportal, and lobular necroinﬂammation and prominent
plasma cells [63]. Serologic evidence of autoimmunity, with. 3 prior to HCV clearance. (A) mild necroinﬂammation in zone 3 (arrows) around
iopsy showing lymphoid inﬁltrate with a small amount of focal interface activity
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Fig. 5. Possible mechanistic pathways for immune mediated complications in interferon-treated HCV positive liver transplant recipients. Interferon alpha (IFNa)
activates a large number of interferon stimulated genes (ISGs), which combined with the upregulation of MHC antigen expression results in increased antigen presentation,
T-cell activation and dominance of a Th1 response including release of TNF a, IL2, IL12, IFNc, FasL, perforin and GrzB activities, and decrease on IL10 and Treg activity,
collectively leading to tissue damage and inﬂammation. Similarly ribavirin (RBV) also potentiates ISGs expression and skewing toward TH response. IFNa also enhances
recruitment and activity of other non-speciﬁc cell types such as natural killer (NK) cells, macrophages, neutophiles, and monocytes. Stimulated virus-speciﬁc T-cells and NK
cells may also lyse allogeneic graft cells, by allo-recognition or lack of self-MHC, respectively. An increased cytolitic activity by NK cells and T-cells may potentially increase
the antigen release, both viral, self (cryptic) and allogeneic, which in turn can trigger proliferation of memory T-cell subsets previously sensitized to viral, and alloantigens.
While expansions of T-cell clones directed to viral antigens contribute to viral load reduction and clearance, expansions of T-cell clones to alloantigens may trigger
autoimmunity. The mechanism underlying the enhancement of autoimmune responses by IFNa may be ampliﬁed in predisposed individuals. Previous B-cell sensitization
(even without detectable auto-antibodies prior to transplantation) and genetic susceptibility (female gender and certain HLA phenotypes) may be risk factors for IFNa-
mediated autoimmunty in HCV patients. Potentially, the increased Ag release induced by IFNa may induce expansion of B-cell clones sensitized to allo- and auto-antigens
that can even lead to accumulation of long-lived plasma cells niches inside the allograft, which in turn produce an elevation of IgG, auto-antibodies, and consequently,
antibody-mediated autoimmune disease including extra-hepatic manifestations. The abundance of auto and allo-antibodies could potentially lead to antibody-mediated
rejection mechanisms through NK/ADCC and complement pathways. Lastly, activated B cells may also amplify T-cell responses, potentially explaining the superimposition
of autoimmune-like hepatitis with acute/chronic cellular rejection.
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either auto-antibodies and/or hypergammaglobulinemia, was
present in 66% of these patients.
In the Fiel and the Khettry studies, the outcome of patients
with plasma-cell rich AIH like features was poor, more than
60% dying from graft failure and portal hypertension.
Ward et al. compared the outcome of 40 HCV-positive liver
transplant recipients with plasma cell hepatitis (PCH) and that
of a control group of HCV recipients who did not develop PCH
(n = 80) [64]. Both groups were matched for their year of trans-
plantation and the availability of biopsy material. PCH patients
were more likely to be female compared to controls (ratio
male/female in the PCH cases 24:16 vs 71:9 in controls). In addi-
tion, PCH patients had worse outcomes than controls (65% vs
40%; p <0.01), including increased mortality (50% vs. 30%,
p <0.05). Kaplan–Meier survival analysis showed signiﬁcantly
worse survival for PCH patients from 4 to 10 years post LT
(p <0.05). Explants from 40% of PCH patients had a score of 3
(plasma cells composing >30% of the inﬁltrate) compared to
18% of control patients [64]. Interestingly, in the study by Khettry
et al. [63], plasmacytic periseptitis on the explant was also more
frequently observed in patients with post-transplant AI-like
hepatitis (89% of the AIH compared to only 31% that either
developed typical recurrent HCV or showed no evidence of HCV
recurrence). These data suggest that HCV recipients with signiﬁ-
cant plasma cell inﬁltrates in their native livers may have an
immunological predisposition to also develop AIH like features
in the allograft.
An AI-like hepatitis has also been reported in liver transplant
recipients treated with PEG and RBV for recurrent hepatitis C
[56,58,65]. In general, these patients have no history of AI dis-
ease, and HCV RNA is undetectable at the time of the secondary
rise in liver enzymes. The latter renders the hypothesis that the
liver allograft damage in these treated patients is truly related
to autoimmunity as opposed to HCV per se, more convincing.
The clinical presentation, including the pattern of aminotransfer-
ase elevation, IgG rise, detectable smooth-muscle antibody, typi-
cal histological features of AIH, and response to therapy (steroids
and azathioprine) is consistent with the diagnosis of post-trans-
plantation immune mediated hepatitis. In fact, in most cases,
the application of the International Diagnostic Criteria for
Autoimmune Hepatitis gives scores consistent with probable or
deﬁnite AIH. Interestingly, the AIH score was generally negative
in these patients prior to antiviral therapy (Table 1).
Berardi et al. [65] reported the largest series of such patients
to date, describing 9 of 44 HCV-positive liver allograft recipients
who developed AI-like hepatitis following at least 6 months of
treatment with PEG and RBV. These patients developed signiﬁ-
cant graft dysfunction and hepatitis despite clearance of HCV
RNA in all but 1 case. Three patients developed other deﬁnite
autoimmune disorders including overlapping anti-mitochondrial
antibody-positive cholangitis, autoimmune thyroiditis and sys-
temic lupus erythematosus, respectively. Withdrawal of antiviral
treatment and introduction of steroids resulted in remission in 5
patients and graft failure and death in two others. The authors
concluded that IFN therapy may have induced this AIH [65].
However, atypical rejection remains a potential cause since some
of the patients had histological evidence of ductopenia suggestive
of CR. Indeed IFN induced CR is a well recognized risk factor for
graft failure (see above).
In the aforementioned study by Fiel, 14 patients (37%)
were receiving IFN therapy at the time of the diagnosis of214 Journal of Hepatology 201PCH with 4/14 having undetectable HCV RNA [62]. An impor-
tant observation in this study was the lack of association
between antiviral therapy for HCV recurrence and the devel-
opment of the histological changes, its resolution, or clinical
outcome.
HCV itself has been shown in the immune competent patient
to be independently associated with a high incidence of autoim-
mune diseases, such as cryoglobulinemia, Sjogren like syndrome
or immune mediated thyroidits, and auto-antibodies, such as
ANA and LKM-1 are frequently detected in HCV-positive patients
[7,9,13,23]. Isolated cases of HCV-associated mixed cryoglobu-
linemia have been reported in the liver transplant population.
In one study, mixed cryoglobulinemia was found in approxi-
mately 20% of the HCV-positive liver transplant recipients
compared to none in the HCV-negative group. Only half of the
patients with detectable cryoglobulins in the serum had
pathological manifestations of cryoglobulinemia [66]. IFN and
ribavirin therapies have both been used in combination and as
monotherapy to treat the exacerbation or reappearance of
HCV-associated cryoglobulinemia after liver transplantation
with variable results [67].
In the non-transplant HCV patients, recognition of AIH like fea-
tures is based on the presence of signiﬁcant plasma cells in the
biopsy and aggressive interface activity. Furthermore, the AIH pat-
tern in HCV patients has been associated with higher serum levels
of gamma-globulin and immunoglobulin G, a higher frequency of
human leukocyte antigen DR3 and high titers of anti-smoothmus-
cle antibodies in serumwhich suggests that in some patients with
a genetic susceptibility to autoimmune phenomena HCV infection
triggers autoimmune processes in the liver that contribute to tis-
sue damage. In addition, IFN and RBV exert a variety of immune
modulatory effects thatmay further trigger autoimmune phenom-
ena [68–71]. Thus, IFN inhibits T-suppressor-cell function, induces
natural killer cells and cytotoxic T lymphocytes, stimulates major
histocompatibility complex class 1 antigen expression, and polar-
izes the adaptive immune response to Th1, which is likely an
important factor in IFN-induced autoimmunity. The combination
of HCV infection and IFN therapy may have a synergistic effect in
triggering autoimmunity. Since most cases occur once HCV RNA
has become negative, one potential hypothesis is that a vigorous
immune response promoting virus clearance also favors tissue
damage with subsequent cryptic antigen release in a context of
interferon-induced major histocomaptibilty complex (MHC) up
regulation (Fig. 5).
None of the risk factors evaluated in the published reports,
including gender, immunosuppression, the use of RBV, and/or
the presence of auto-antibodies were found to be associated with
the development of the AI phenomena during antiviral therapy.
Interestingly, Lodato et al. reported a potential protective role
of granulocyte colony stimulating factor (G-CSF) [72]. In this
study, de novo AIH occurred in 9/45 of the non-GCSF group vs
0/23 in the GCSF group (p <0.03). The immunomodulatory effect
of G-CSF on human CD4+ T cells, with skewing T-cell differentia-
tion toward the Th2 phenotype, and subsequent suppression of T
cell alloreactivity may, in part, explain this association [72].
However, this potentially beneﬁcial GCSF effect needs to be
conﬁrmed by others and validated in well-designed prospective
studies.
Although infrequently, there have been cases of AIH, including
some with fulminant presentation [73], triggered by interferon-
ribavirin treatment in the non-transplant setting [71].1 vol. 55 j 207–217
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Unresolved question
Apart from the many unresolved questions already mentioned
above, the most challenging clinical problem, perhaps, is how
to distinguish AIH from ACR, and both from recurrent HCV, in
the presence and absence of IFN-based antiviral therapy. It has
been suggested that ACR should be diagnosed when the
immune response is directed primarily at an antigen unique
to the allograft liver, while AIH in contrast should be diagnosed
when tissue damage is mediated by memory cells in the recip-
ients [74]. However in daily practice distinguishing the two
diagnoses remains based on surrogate markers. The proportion
of plasma cells in the inﬁltrate is currently used as an important
marker together with the presence of bile duct damage and the
severity of the interface activity. Rejection-related inﬁltrates
usually contain less than 30% plasma cells; the majority of bile
ducts exhibit lymphocytic damage with mild interface activity
[51]. Interface activity is more severe in AIH with less bile duct
damage with a higher proportion of plasma cells than in ACR
[51]. These criteria need to be validated prospectively for their
reproducibility.
Another unresolved issue is the signiﬁcance of central perive-
nulitis (CPV) in HCV recipients. CPV described as zone 3 inﬂam-
mation surrounding the hepatic vein with or without associated
necrosis is a distinct immune mediated histopathologic process
occurring in the liver allograft for which several etiologies includ-
ing ACR, CR, AIH, or recurrence of chronic HCV have been postu-
lated [75].
When occurring within the ﬁrst weeks post liver transplanta-
tion, CPV presents characteristic features of perivenular inﬂamma-
tion in associationwith characteristic portal tract changes of acute
rejection [51].More frequently, features of isolated CPV are seen in
patients presentingwith graft dysfunction severalmonths ormore
following transplantation [75]. In this ‘late CPV’ cases, hepatic
venous endothelial inﬂammation is rarely present and portal tract
inﬂammation is variable in severity and composition and often
lacks the typical features seen in early ACR [75]. Late CPV is often
associated with long term graft injury, including CR and de novo
AIH [76]. Therefore, it may be warranted to consider CPV present-
ing at anytime point post liver transplantation as a form of cellular
rejection [76]. Should this, indeed, hold true, treatment with
increased immunosupressionmaybe indicatedeven in the context
of recurrent HCV, as it may prevent the morbidity due to late graft
failure and progressive parenchymal injury leading to signiﬁcant
ﬁbrosis (Fig. 3C). This clearly requires more data, ideally from pro-
spective controlled trials.
In conclusion, both immune-mediated complications associ-
ated with IFN-based therapy in HCV-infected liver transplant
recipients, including AIH-like hepatitis and acute or chronic
rejection; tend to occur in the context of a strong anti-HCV
immune response with relatively low or undetectable viremia.
To differentiate these entities in clinical practice currently relies
largely on histopathology and, to a lesser extent, on autoimmune
serological markers. A better understanding of the underlying
cellular pathomechanisms will be required to develop diagnostic
markers with improved accuracy, as well as more speciﬁc strate-
gies for prevention and treatment.Financial support
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